- 1 Critical care demand and intensive care supply for patients in Japan with COVID-19 at the
- time of the state of emergency declaration in April 2020: a descriptive analysis
- 4 Yosuke Fujii, MD \*, Kiichi Hirota, MD, PhD
- 5 Department of Human Stress Response Science, Institute of Biomedical Science, Kansai
- 6 Medical University, Osaka, Japan
- 7 \* Correspondence: yofujii-kyt@umin.ac.jp
- 9 **Keywords:** severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); The
- coronavirus disease 2019 (COVID-19); intensive care unit (ICU); extracorporeal membrane
- 11 oxygenation (ECMO)

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

**Abstract Background:** The coronavirus disease 2019 (COVID-19) pandemic overwhelms Japan's intensive care capacity. This study aimed to determine the number of patients with COVID-19 who required intensive care and to compare the numbers with Japan's intensive care capacity. Methods: Publically available datasets were used to obtain the number of confirmed patients with COVID-19 undergoing mechanical ventilation and extracorporeal membrane oxygenation (ECMO) between February 15 and July 19, 2020, to determine and compare intensive care unit (ICU) and attending bed needs for patients with COVID-19, and to estimate peak ICU demands in Japan. **Results:** During the epidemic peak in late April, 11443 patients (1.03/10000 adults) had been infected, 373 patients (0.034/10000 adults) were in ICU, 312 patients (0.028/10000 adults) were receiving mechanical ventilation, and 62 patients (0.0056/10000 adults) were under ECMO per day. At the peak of the epidemic, the number of infected patients was 651% of designated beds, and the number of patients requiring intensive care was 6.0% of ICU beds, 19.1% of board-certified intensivists, and 106% of designated medical institutions in Japan. **Conclusions:** The number of critically ill patients with COVID-19 continued to rise during the pandemic, exceeding the number of designated beds but not exceeding ICU capacity.

## Introduction

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

A novel coronavirus, namely, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first reported in Wuhan, China, in December 2019, and the number of newly reported cases has continued to increase globally. As of September 2020, >34 million cases had been reported worldwide and >1000000 people had died [1], with >84000 reported cases and >1500 deaths recorded in Japan. On January 30, 2020, the World Health Organization (WHO) declared the epidemic to be a "public health emergency of international concern". On April 7, 2020, Japan declared a state of emergency in seven major central cities, which then was extended to all 47 prefectures on April 16, 2020 [2]. COVID-19 affects the respiratory system and patients infected with SARS-CoV-2 suffer from respiratory syndromes [3]. Although approximately 70-80% of patients with COVID-19 have mild to moderate symptoms and recover, 5-20% of patients develop severe respiratory failure and may require admission to an intensive care unit (ICU) [3-5]. Symptomatic treatment for severe respiratory failure has involved the use of mechanical ventilation and extracorporeal membrane oxygenation (ECMO) [5-9] although there are candidate drugs available to treat severe patients with COVID-19 as of September 2020 [10,11]; remdesivir [12,13] and dexamethasone [14]. One study that analyzed clinical cases of COVID-19 reported a better prognosis in patients with a mild infection, whereas the prognosis for patients with severe and critical infections is poor. However, patients presenting with mild infection are less obvious and are less easily located or identified [15]. A previous observational study reported that approximately 50% of the patients admitted to ICU required ventilation support and, of these, one in four patients required considerably

greater levels of intensive life support [15]. A cohort study found that approximately 8% of

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

patients with COVID-19 were critically ill [16]. One case series reported that, of 18 patients who required intubation, 1 patient required ECMO and 5 patients died [17]. It has been estimated that, despite intensive life support, approximately 3-4% of all infected patients are likely to die due to SARS-CoV-2 infection [3,18]. The importance of ICUs during the COVID-19 pandemic has been well established; however, ICU capacity concerning expected numbers of patients with COVID-19 requiring intensive care is unknown. During the COVID-19 epidemic, there has been a dramatic surge in the number of critically ill patients with an urgent need for ICU admission [19], as occurred in other natural disasters [20,21]. An analysis of the epidemic peak in Wuhan indicated that the number of severely and critically ill adult patients requiring intensive care was estimated to be 12.2/10000 and 2.6/10000, respectively [22]. However, this situation differs between countries, and specific data sourced in terms of Japanese circumstances are needed [23]. This study aimed to determine the number of critically ill patients who required ICU admission, including the number of patients requiring mechanical ventilation and ECMO, and to compare these patient numbers with ICU capacity in Japan at nationwide and regional levels. **Materials and Methods** Ethical approval Institutional review board approval and patient informed consent were not required for this

study, as this study did not involve human participant research or any interventions.

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

Infectious disease data source We obtained data concerning numbers of infected, recovered, and dead patients due to COVID-19 in Japan from a publicly available website [24]. The number of patients who required mechanical ventilation and ECMO support was extracted from the Japanese Society of Intensive Care Medicine (JSICM) website [23,25]. This database accumulates data using a CRoss Icu Searchable Information System (CRISIS). More than 570 facilities across Japan currently participate in this CRISIS, centering on facilities certified by the JSICM and facilities designated by the Japanese Society of Emergency Medicine, with a total of 5500 ICU beds, covering 80% of the total ICU beds in Japan [26]. This database provides information concerning the number of patients under mechanical ventilation, under ECMO, the number of patients in recovery from ECMO, and the number of patients who died during ECMO. Intensive care unit capacity data source We extracted the number of ICU beds (n = 7109) and board-certified intensivists (n = 1957) from the JSICM website. This website has also reported the estimated number of mechanical ventilators for adults (n = 30091) and ECMO machines (n = 2208) in Japan (table 1) [27]. In Japan, COVID-19 was designated as an infectious disease under the Infectious Diseases Control Law on January 28, 2020. Patients with COVID-19 were admitted and transferred to designated medical institutions responsible for the hospitalization of patients with a

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

Category II infectious disease (especially tuberculosis) or a novel influenza infection. Although clear evidence of person-to-person airborne transmission of SARS-CoV-2 has not been established, an airborne component of transmission is likely, based on other respiratory viruses such as severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and influenza [28-31] and its presence in aerosol has been confirmed at RNA level [32,33]. Many infectious control guidelines recommend that healthcare workers be protected through the use of personal protective equipment [34-36]. Suspicious airborne infectious routes make patient care difficult and complex, requiring the management of the patient using airborne precautions [37] or management of the patient in a depressurized area [36]. A patient management ratio of one critically ill patient to one depressurized area per hospital has been used, assuming that not all infected patients could be treated in ICU beds. In Japan, there are 1758 beds designated for patients with a Category II infectious disease, 3502 beds allocated for patients with tuberculosis, and 351 designated medical institutions for patients with Category II infectious diseases (table 1) [38]. ECMO is a highly integrated critical care treatment that requires multidisciplinary team collaboration [39,40]. It is also assumed that not all of the ECMO machines in Japan could be allocated to manage critically ill patients with COVID-19. In Japan, an organized ECMO-based respiratory program, namely, the ECMO project [41], comprises a consortium of specialized institutions for ECMO involving the participation of 100 hospitals in this project. We assumed these hospitals were the institutions specially

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

dedicated to treating critically ill patients with COVID-19 who required treatment using ECMO machines (table 1) [41]. Board-certified intensivists and patient numbers in ICUs in seven regions in Japan according to the JSICM and CRISIS Data concerning population numbers in Japan in 2019 at nationwide and regional levels and the proportion of adults aged ≥15 years were retrieved from the Statistics Bureau of Japan [42]. The national population was  $1.26 \times 10^8$  and the proportion of adults was 87.9%. To determine regional differences, we analyzed the demand and supply of ICUs in the 47 prefectures. The JSICM and CRISIS have reported the number of board-certified intensivists and the number of patients in ICU in seven regions in Japan, namely, Hokkaido, Tohoku, Kanto-Koshinetsu, Tokai-Hokuriku, Kansai, Chugoku-Shikoku, and Kyusyu-Okinawa (figure 1). Data concerning the 47 prefectures were then integrated according to these seven regions (table 1). Statistical analysis The total number of patient days in ICU was summed to estimate the total number of ICU days and the raw number of patients in ICU on each day was plotted [22]. The notation "critical case" denoted the total number of patients on mechanical ventilator and ECMO. The proportion of critically ill patients per 10000 adults was estimated based on the number presented in the infectious diseases and ICU capacity data source sections.

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

**Results** COVID-19 accounted for a total of 21705 ICU days, 18495 mechanical ventilation days, and 3210 ECMO days between January 15, 2020, and July 19, 2020, with a median (interquartile range [IQR]) of 96 (68-197) patients in ICU, 83 (58-174) patients on mechanical ventilation, and 15 (11-27) patients on ECMO machines each day during these 156 days (figure 2 and table 2). During the peak of the epidemic in late April 2020, 11443 patients (1.03 per 10000 adults) had been infected with SARS-CoV-2 and, of these, 373 patients (0.034 per 10000 adults) were admitted to ICU, 312 patients (0.028 per 10000 adults) were treated using mechanical ventilation, and 62 patients (0.0056 per 10000 adults) were treated using ECMO machines per day. The number of infected patients at the peak of the epidemic was 651% of total designated beds for Category II infectious disease and 218% of total Category II with tuberculosis beds, and the number of patients requiring intensive care at the peak of the epidemic was 6.0% of total ICU beds in Japan, 19.1% of total board-certified intensivists in Japan, and 106% of total Category II institutions. The number of patients requiring ECMO at the peak of the epidemic was 3.2% of total board-certified intensivists in Japan, 17.7% of total Category II institutions, and 62% of total hospitals participating in ECMO project in Japan, respectively (figure 2 and table 3). The number of total ICU days was 1766 (IQR, 8-13) in Hokkaido, 200 (0-2) days in Tohoku, 11805 (40-106) days in Kanto-Koshinetsu, 1318 (5-12) days in Tokai-Hokuriku, 4587 (6-48) days in Kansai, 367 (0-3) days in Chugoku-Shikoku, and 1662 (1-17) days in Kyusyu-Okinawa (figure 3 and table 2).

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

ICU demand compared with the proportion of board-certified intensivists greatly increased in Hokkaido (37.3% of total board-certified intensivists in Hokkaido), in Kanto-Koshinetsu (26.7%), and Kansai (27.7%) compared with the overall demand in Japan (19.1%). ICU and mechanical ventilation demand overwhelmed the number of Category II institutions in Hokkaido (117% of total Category II institutions of ICU and 108% of total Category II institutions for mechanical ventilation), in Kanto-Koshinetsu (213% for ICU and 176% for mechanical ventilation), and Kansai (262% for ICU and 241% for mechanical ventilation) (table 3). The number of patients requiring ECMO compared with the number of ECMO project hospitals was 125% in Hokkaido and 106% in Kanto-Koshinetsu (figure 4 and table 3). **Discussion** The number of new patients diagnosed with COVID-19 continues to increase globally. Approximately 70-80% of patients infected with SARS-CoV-2 show mild to moderate respiratory symptoms; however, between 5% and 32% of these patients may develop severe symptoms and require ICU admission, of whom between 3% and 22% may require mechanical ventilation and between 0.5% and 5% may require oxygenation with ECMO [3,4,15,37,43-45]. Depending on the efficacy of infection control strategies, a shortage of ICU ventilators may or may not eventuate [41]. Exceeding hospital bed capacity would likely increase the community spread of SARS-CoV-2 and lead to decreased quality of healthcare and intensive care [22]. In China, national lockdown, quarantine, and social distancing measures were adopted to control the

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

spread of infection, with >10000 beds designated for the isolation and treatment of patients with confirmed COVID-19 by early February 2020 [22]. Despite these efforts to control the spread of infection, this did not lead to an immediate downturn in demand for hospitalization in critical care units and ICUs in China [22], and this situation has been similar in Japan. Our results indicated a critical need to isolate and treat patients with COVID-19; however, while there remained a small margin for critically ill patients requiring mechanical ventilation and ECMO in terms of ICU capacity, this situation was sub-optimal. Intensivists do not necessarily attend to all critically ill patients and have been reported to provide care to only 37% of all ICU patients [46]. In the United States, one study reported that only approximately 30% of intensive care units were staffed by dedicated intensivists [47]. Due to different health care systems, statistics from the United States model could not be simply extrapolated to Japan, but we have assumed that these percentages are likely to be the same or no greater in Japan. The number of critically ill patients in ICU at the peak of the epidemic accounted for 19% of total board-certified intensivists in Japan, which challenged Japan's ICU capacity. Our findings also showed a regional bias in terms of ICUs being overwhelmed in Japan. Kanto-Koshinetsu and Kansai are the biggest regions in Japan. The Kanto-Koshinetsu region includes Japan's capital city, Tokyo, which is the most populous prefecture and also includes Kanagawa, which is the second most populous prefecture. The Kansai region includes Osaka, which is the third most populous prefecture. A large population and the movement of people to and from these regions is thought to have spread the infection,

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

which resulted in medical capacity becoming overwhelmed. Hokkaido, the largest prefecture in Japan, had an increase in the number of patients with COVID-19 in the early phase of the epidemic. Epidemiological evidence to explain this phenomenon remains limited. Before the administration's state of emergency declaration, the local government in Hokkaido issued its emergency declaration on February 28, 2020, to control the spread of infection [48]. ECMO management in Japanese hospitals has previously resulted in poorer outcomes [49] compared with those reported in other countries during the N1H1 influenza epidemic [39,50-54]. There is a wide consensus that ECMO treatment should be performed at centers with high case volumes and established protocols, and involving clinicians who are experienced in its use. Patients who require ECMO treatment should be transferred to appropriate ECMO centers [39,40,49,54]. Japan has introduced an ECMO project [41] and the ECMOnet [23,25], which involve a consortium working to promote the appropriate use of ECMO, to help develop an evidence-based foundation for its use, to strive for continuous improvement in its application where appropriate, and to collect data concerning the number of patients requiring mechanical ventilation and ECMO support [55,56]. There are >2000 ECMO machines available for use in Japan. The number of patients requiring ECMO was 3.2% of all ECMO machines at the peak of the epidemic, but the capacity levels in terms of use should not be overestimated. In terms of the hospitals participating in the ECMO project in Japan, the number of patients requiring ECMO was 62% of their work at the peak of the epidemic, which is likely to provide a more realistic estimate of their intensive care capacity.

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

Our study had several limitations. First, the number of critically ill patients requiring intensive care was not completely addressed in the JSICM database. This database has been estimated to capture >80% of clinical cases [25,26]; however, it relies heavily on the cooperation of physicians struggling to treat large numbers of critically ill patients. Second, the extent of the ICU capacity and the number of patients requiring admission to ICUs were not completely validated. The JSICM reported the estimated number of ventilators and ECMO machines according to responses to a questionnaire sent to its member hospitals. Therefore, there was a risk of overestimating ICU capacity. Third, the assumption of one critically ill patient to one depressurized area per hospital did not necessarily reflect the real-life situation. For example, one author's institution was designated as a Category II infectious diseases institution with eight ICU beds, one depressurized area, and six Category II beds, with one board-certified intensivist. This institution was not a member of the ECMO project. Six Category II beds were fully occupied as soon as the number of infected patients threatened to overwhelm the capacity of the ICU, and other wards were then rearranged to manage patients with mild manifestations of COVID-19. There were two alternatives to treat critically ill patients with COVID-19: one was to use an ICU depressurized bed, and the other was to rearrange the beds in the emergency department. The latter option was chosen because other critically ill and surgical patients could not be treated in the ICU when occupied by patients with COVID-19 for fear of airborne transmissions. Most hospitals are thought to have flexibly employed a variety of methods to increase their capacity to treat patients with COVID-19.

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

**Conclusions** During the COVID-19 pandemic and following the state of emergency declaration in Japan, the number of patients threatened to overwhelm the number of beds designated for infectious patients; however, Japan's ICU capacity was sufficient to withstand the demands for mechanical ventilation and ECMO. However, there is no room for complacency in this situation. Urgent consideration is needed concerning future planning concerning how to mitigate the threat to providing intensive care for critically ill patients with COVID-19 at domestic and regional levels in Japan. **Author Contributions:** Conceptualization, Y.F. and K.H.; methodology, Y.F.; formal analysis, Y.F.; investigation, Y.F.; data curation, Y.F.; writing—original draft preparation, Y.F.; writing—review and editing, Y.F. and K.H.; visualization, Y.F.; supervision, K.H.; project administration, Y.F. and K.H.; funding acquisition, K.H. All authors have read and agreed to the published version of the manuscript. **Funding** This research and the APC were funded by the branding program as a worldleading research university on intractable immune and allergic diseases from MEXT Japan to K.H. **Acknowledgments:** The authors would like to thank Editage (www.editage.com) for English language editing. **Conflicts of Interest:** The authors declare no conflict of interest. **Abbreviations** 

## The following abbreviations are used in this manuscript:

WHO World Health Organization

ECMO Extracorporeal membranous oxygenation

COVID-19 Coronavirus induced disease 2019

SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2

ICU Intensive care unit

JSICM The Japanese Society of Intensive Care Medicine

CRISIS CRoss Icu Searchable Information System

IQR Interquartile range

273

## References

- World Health Organization. "Coronavirus Disease (COVID-19) Pandemic".
   Accessed September 30, 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019.
- Cabinet Secretariat. "Japan's Response to the Novel Coronavirus Disease:
   Declaration of a State of Emergency" (April 7, 2020). Accessed September 30, 2020. https://corona.go.jp/en/.
- 3. Fu L, Wang B, Yuan T, et al. (2020) Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: A systematic review and meta-analysis. J Infect 80:656–665 doi: 10.1016/j.jinf.2020.03.041
- Chen N, Zhou M, Dong X, et al. (2020) Epidemiological and clinical characteristics
   of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive
   study. Lancet 395:507–513 doi: 10.1016/S0140-6736(20)30211-7
- 5. Hong X, Xiong J, Feng Z, Shi Y (2020) Extracorporeal membrane oxygenation (ECMO): does it have a role in the treatment of severe COVID-19? Int J Infect Dis 94:78–80 doi: 10.1016/j.ijid.2020.03.058
- 6. Firstenberg MS, Stahel PF, Hanna J, et al. (2020) Successful COVID-19 rescue therapy by extra-corporeal membrane oxygenation (ECMO) for respiratory failure: a case report. Patient Saf Surg 14:20 doi: 10.1186/s13037-020-00245-7
- 7. Taniguchi H, Ogawa F, Honzawa H, et al. (2020) Veno-venous extracorporeal membrane oxygenation for severe pneumonia: COVID-19 case in Japan. Acute Med Surg 7:e509 doi: 10.1002/ams2.509
- MacLaren G, Fisher D, Brodie D (2020) Preparing for the Most Critically Ill Patients
   With COVID-19: The Potential Role of Extracorporeal Membrane Oxygenation.
   JAMA doi: 10.1001/jama.2020.2342
- Hartman ME, Hernandez RA, Patel K, et al. (2020) COVID-19 Respiratory Failure:
   Targeting Inflammation on VV-ECMO Support. ASAIO J 66:603–606 doi:
   10.1097/MAT.000000000001177
- 303 10. Bhimraj A, Morgan RL, Shumaker AH, et al (2020) Infectious Diseases Society of
   304 America Guidelines on the Treatment and Management of Patients with COVID-19.
   305 Clin Infect Dis. doi: 10.1093/cid/ciaa478
- 306 11. Alhazzani W, Møller MH, Arabi YM, et al (2020) Surviving Sepsis Campaign:
   307 guidelines on the management of critically ill adults with Coronavirus Disease 2019
   308 (COVID-19). Intensive Care Med 46:854–887. doi: 10.1007/s00134-020-06022-5
- 12. Beigel JH, Tomashek KM, Dodd LE, et al (2020) Remdesivir for the Treatment of Covid-19 Preliminary Report. N Engl J Med. doi: 10.1056/NEJMoa2007764
- 311 13. Wang Y, Zhang D, Du G, et al (2020) Remdesivir in adults with severe COVID-19: a
   312 randomised, double-blind, placebo-controlled, multicentre trial. Lancet 395:1569–
   313 1578. doi: 10.1016/S0140-6736(20)31022-9
- 14. RECOVERY Collaborative Group, Horby P, Lim WS, et al (2020) Dexamethasone in
   Hospitalized Patients with Covid-19 Preliminary Report. N Engl J Med. doi:
   10.1056/NEJMoa2021436

- Wang D, Hu B, Hu C, et al. (2020) Clinical Characteristics of 138 Hospitalized
   Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA
- doi: 10.1001/jama.2020.1585
- Liang W, Liang H, Ou L, et al. (2020) Development and Validation of a Clinical Risk
   Score to Predict the Occurrence of Critical Illness in Hospitalized Patients With
   COVID-19. JAMA Intern Med doi: 10.1001/jamainternmed.2020.2033
- 17. Wang J, Lu F, Zhou M, et al. (2020) Tracheal intubation in patients with severe and critical COVID-19: analysis of 18 cases. Journal of Southern Medical University 40:337–341 doi: 10.12122/j.issn.1673-4254.2020.03.07
- 18. Sun P, Qie S, Liu Z, et al. (2020) Clinical characteristics of hospitalized patients with SARS-CoV-2 infection: A single arm meta-analysis. J Med Virol 92:612–617 doi: 10.1002/jmv.25735
- 329 19. Qiu H, Tong Z, Ma P, et al. (2020) Intensive care during the coronavirus epidemic.
   330 Intensive Care Med 46:576–578 doi: 10.1007/s00134-020-05966-y
- 20. Devereaux A, Christian MD, Dichter JR, et al. (2008) Summary of suggestions from the Task Force for Mass Critical Care summit, January 26-27, 2007. Chest 133:1S-7S doi: 10.1378/chest.08-0649
- 21. Rubinson L, Hick JL, Curtis JR, et al. (2008) Definitive care for the critically ill during a disaster: medical resources for surge capacity: from a Task Force for Mass Critical Care summit meeting, January 26-27, 2007, Chicago, IL. Chest 133:32S-50S doi: 10.1378/chest.07-2691
- 22. Li R, Rivers C, Tan Q, et al. (2020) Estimated Demand for US Hospital Inpatient and
   Intensive Care Unit Beds for Patients With COVID-19 Based on Comparisons With
   Wuhan and Guangzhou, China. JAMA Netw Open 3:e208297 doi:
   10.1001/jamanetworkopen.2020.8297
- Japan ECMOnet for COVID-19, Shime N (2020) Save the ICU and save lives during
   the COVID-19 pandemic. J Intensive Care 8:40 doi: 10.1186/s40560-020-00456-1
- 344 24. worldometer. "Japan Coronavirus". Accessed September 30, 2020.
   345 https://www.worldometers.info/coronavirus/country/japan/.
- Japan ECMOnet for COVID-19. "Status of Severe COVID-19 Patients". Accessed
   September 30, 2020. https://crisis.ecmonet.jp/.
- 348 26. Osamu, N (May 13, 2020). Accessed September 30, 2020. https://www.covid19-jmamedical-expert-meeting.jp/topic/1121. article in Japasene.
- Japanese Society of Intensive Care Medicine, Society of Respiratory Care Medicine,
   and Japan Association for Clinical Engineer. "Estimate of the Number of Ventilator,
   Etc, in Japanese Hospitals". Accessed September 30, 2020.
   https://www.jsicm.org/news/news200514.html.
- 28. Setti L, Passarini F, De Gennaro G, et al. (2020) Airborne Transmission Route of
   COVID-19: Why 2 Meters/6 Feet of Inter-Personal Distance Could Not Be Enough.
   Int J Environ Res Public Health 17: doi: 10.3390/ijerph17082932
- 29. Anderson EL, Turnham P, Griffin JR, Clarke CC (2020) Consideration of the Aerosol
   Transmission for COVID-19 and Public Health. Risk Analysis 40:902–907 doi:
   10.1111/risa.13500

- 30. Morawska L, Cao J (2020) Airborne transmission of SARS-CoV-2: The world should face the reality. Environ Int 139:105730 doi: 10.1016/j.envint.2020.105730
- 31. Wilson NM, Norton A, Young FP, Collins DW (2020) Airborne transmission of severe acute respiratory syndrome coronavirus-2 to healthcare workers: a narrative review. Anaesthesia doi: 10.1111/anae.15093
- 32. Liu Y, Ning Z, Chen Y, et al. (2020) Aerodynamic analysis of SARS-CoV-2 in two Wuhan hospitals. Nature 582:557–560 doi: 10.1038/s41586-020-2271-3
- 33. Wang J, Feng H, Zhang S, et al. (2020) SARS-CoV-2 RNA detection of hospital isolation wards hygiene monitoring during the Coronavirus Disease 2019 outbreak in a Chinese hospital. Int J Infect Dis 94:103–106 doi: 10.1016/j.ijid.2020.04.024
- 34. Wax RS, Christian MD (2020) Practical recommendations for critical care and anesthesiology teams caring for novel coronavirus (2019-nCoV) patients. Can J Anaesth 67:568–576 doi: 10.1007/s12630-020-01591-x
- 373 35. Ferioli M, Cisternino C, Leo V, et al. (2020) Protecting healthcare workers from SARS-CoV-2 infection: practical indications. Eur Respir Rev 29: doi: 10.1183/16000617.0068-2020
- 36. Chigurupati R, Panchal N, Henry AM, et al. (2020) Considerations for Oral and
   Maxillofacial Surgeons in COVID-19 Era: Can We Sustain the Solutions to Keep Our
   Patients and Healthcare Personnel Safe? Journal of Oral and Maxillofacial Surgery
   S0278239120305516 doi: 10.1016/j.joms.2020.05.027
- 37. Huang C, Wang Y, Li X, et al. (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet 395:497–506 doi: 10.1016/S0140-6736(20)30183-5
- 38. Ministry of Health, Labour, and Welfare. "Status of Designation of Class II

  384 Designated Medical Institutions for Infectious Diseases" (April 1, 2019). Accessed

  385 September 30, 2020. https://www.mhlw.go.jp/bunya/kenkou/kekkaku
  386 kansenshou15/02-02-01.html.
- 39. Haeck JD, Dongelmans DA, Schultz MJ (2012) ECMO Centers and Mortality From Influenza A(H1N1). JAMA 307: doi: 10.1001/jama.2012.57
- 40. Brodie D, Bacchetta M (2011) Extracorporeal Membrane Oxygenation for ARDS in
   Adults. N Engl J Med 365:1905–1914 doi: 10.1056/NEJMct1103720
- Japanese Society of Respiratory Care Medicine. "ECMO Project". Accessed
   September 30, 2020. http://square.umin.ac.jp/jrcm/contents/ecmo/index.html.
- 393 42. Statistics Bureau of Japan. "Population Statistics on 2019" (October 1, 2019).
   394 Accessed September 30, 2020. https://www.stat.go.jp/data/jinsui/2019np/index.html.
- Zhou F, Yu T, Du R, et al. (2020) Clinical course and risk factors for mortality of
   adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.
   Lancet 395:1054–1062 doi: 10.1016/S0140-6736(20)30566-3
- 44. Richardson S, Hirsch JS, Narasimhan M, et al. (2020) Presenting Characteristics,
   Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in
   the New York City Area. JAMA doi: 10.1001/jama.2020.6775
- 45. Guan W-J, Ni Z-Y, Hu Y, et al. (2020) Clinical Characteristics of Coronavirus
   Disease 2019 in China. N Engl J Med 382:1708–1720 doi: 10.1056/NEJMoa2002032

- 46. Lois M (2014) The shortage of critical care physicians: is there a solution? J Crit Care 29:1121–1122 doi: 10.1016/j.jcrc.2014.08.001
- 47. Gutsche JT, Kohl BA (2007) Who should care for intensive care unit patients? Crit Care Med 35:S18-23 doi: 10.1097/01.CCM.0000252907.47050.FE
- 48. Hokkaido Government. "Declarations a State of Emergency in Hokkaido" (February 28, 2020). Accessed September 30, 2020. http://www.pref.hokkaido.lg.jp/ss/tkk/koronasengen.htm.
- 49. Takeda S, Kotani T, Nakagawa S, et al. (2012) Extracorporeal membrane
   oxygenation for 2009 influenza A(H1N1) severe respiratory failure in Japan. J Anesth
   26:650–657 doi: 10.1007/s00540-012-1402-x
- 50. Checkley W (2011) Extracorporeal Membrane Oxygenation as a First-Line Treatment Strategy for ARDS: Is the Evidence Sufficiently Strong? JAMA 306:1703 doi: 10.1001/jama.2011.1504
- 51. Noah MA, Peek GJ, Finney SJ, et al. (2011) Referral to an extracorporeal membrane oxygenation center and mortality among patients with severe 2009 influenza A(H1N1). JAMA 306:1659–1668 doi: 10.1001/jama.2011.1471
- 419 52. Laudi S, Busch T, Kaisers U (2010) Extracorporeal membrane oxygenation for 420 ARDS due to 2009 influenza A(H1N1). JAMA 303:941; author reply 942 doi: 421 10.1001/jama.2010.200
- 422 53. Australia and New Zealand Extracorporeal Membrane Oxygenation (ANZ ECMO)
   423 Influenza Investigators, Davies A, Jones D, et al. (2009) Extracorporeal Membrane
   424 Oxygenation for 2009 Influenza A(H1N1) Acute Respiratory Distress Syndrome.
   425 JAMA 302:1888–1895 doi: 10.1001/jama.2009.1535
- 54. Peek GJ, Mugford M, Tiruvoipati R, et al. (2009) Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial.

  Lancet 374:1351–1363 doi: 10.1016/S0140-6736(09)61069-2
- Japan ECMOnet for COVID-19 (2020) Japan ECMOnet for COVID-19: telephone
   consultations for cases with severe respiratory failure caused by COVID-19. J
   Intensive Care 8:24 doi: 10.1186/s40560-020-00440-9
- Japan ECMOnet for COVID-19 (2020) Nationwide system to centralize decisions
   around ECMO use for severe COVID-19 pneumonia in Japan (Special
   Correspondence). J Intensive Care 8:29 doi: 10.1186/s40560-020-00445-4

Figure 1. Seven regions in Japan defined by the Japanese Society of Intensive Care Medicine. Seven regions are Hokkaido, Tohoku (Aomori, Iwate, Akita, Miyagi, Yamagata, and Fukushima), Kanto-Koshinetsu (Ibaraki, Tochigi, Gumma, Saitama, Chiba, Tokyo, Kanagawa, Niigata, Yamanashi, and Nagano), Tokai-Hokuriku (Toyama, Ishikawa, Fukui, Gifu, Shizuoka, Aichi, and Mie), Kansai (Shiga, Kyoto, Osaka, Hyogo, Nara, and Wakayama), Chugoku-Shikoku (Tottori, Shimane, Okayama, Hiroshima, Yamaguchi, Tokushima, Kagawa, Ehime, and Kochi), and Kyushu-Okinawa (Fukuoka, Saga, Nagasaki, Kumamoto, Oita, Miyazaki, Kagoshima, and

Okinawa).

Figure 2. The burden of critical coronavirus disease during the epidemic in Japan. (A) The number of infected and critically ill patients per 1000 adults. Critically ill patients were the sum of the number of patients under mechanical ventilation and ECMO. The Japanese government also declared "The State of Emergency" on 7 April 2020 for major central cities with a cumulative 4257 confirmed cases and 93 deaths among patients with COVID-19 and it spread to all of 47 prefectures on 16 April 2020. (B) The magnified version of figure A. Category II; designated medical institutions for Category II infectious diseases, TB; tuberculosis, ECMO; extracorporeal membrane oxygenation.

Figure 3. The burden of critical coronavirus disease during the epidemic in seven regions defined by the Japanese Society of Intensive Care Medicine in Japan. Raw count of COVID-19 patients under critical care (A), mechanical ventilation (B), and ECMO (C), percentage of patients to the number of board-certified intensivists for critical care (D), mechanical ventilation (E), and ECMO (F), and percentage of patients to the number of Category II institutions for critical care (G), mechanical ventilation (H), and ECMO (I), respectively. Category II; designated medical institutions for Category II infectious diseases, ECMO; extracorporeal membrane oxygenation.

Figure 4. The burden of critical coronavirus disease requiring ECMO to the number of ECMO project hospitals during the epidemic in seven regions defined by the Japanese Society of Intensive Care Medicine in Japan. ECMO; extracorporeal membrane oxygenation.

	Hokkaido Tohoku		Kanto-	Tokai-	Voncoi	Chugoku-	Kyusyu-	
	поккашо	TOHOKU	Koshinetsu Hokuriku		Kansai	Shikoku	Okinawa	Japan
Prefecture	1	6	10	7	6	9	8	47
Population								
( 10 <sup>5</sup> adults)	468.5	769.8	4287	1565.3	1805.4	966.6	1233.4	11075.4
Category II beds	92	171	531	220	238	206	300	1758
	(0.02)	(0.022)	(0.012)	(0.014)	(0.013)	(0.021)	(0.024)	(0.016)
Category II	153	261	937	513	616	397	625	3502
+ TB beds	(0.033)	(0.034)	(0.022)	(0.033)	(0.034)	(0.041)	(0.051)	(0.032)
Intensivist	75 (0.016)	95 (0.012)	727 (0.017)	233 (0.015)	368 (0.02)	228 (0.024)	231 (0.019)	1957 (0.018)
Category II	24	40	91	46	39	42	69	351
institution	(0.005)	(0.005)	(0.002)	(0.003)	(0.002)	(0.004)	(0.006)	(0.003)
ECMO project	4	8	35	11	24	6	12	100
hospital*	(0.0085)	(0.0104)	(0.0082)	(0.007)	(0.0133)	(0.0062)	(0.0097)	(0.009)

**Table 1.** Critical care capacity in Japan and seven regions. The raw count and the proportional count per 10000 adults in parenthesis were listed. \*: 100000 adults.

Category II; designated medical institutions for Category II infectious diseases, TB; tuberculosis, ECMO; extracorporeal membrane oxygenation.

			Kanto- Tokai-			Chugoku-	Kyusyu-		
	Hokkaido	Tohoku	Koshinetsu	Hokuriku	Kansai	Shikoku	Okinawa	Japan	
critical case	1766	200	11805	1318	4587	367	1662	21705	
	[8, 10, 13]	[0, 1, 2]	[40, 51, 106]	[5, 8, 12]	[6, 17, 48]	[0, 2, 3]	[1, 10, 17]	[68, 96, 197]	
ventilation	1547	170	9820	1102	4188	358	1310	18495	
	[7, 9, 12]	[0, 1, 1]	[30, 44, 93]	[4, 7, 10]	[6, 14, 44]	[0, 2, 3]	[1, 9, 14]	[58, 83, 174]	
ЕСМО	219	30	1985	216	399	9	352	3210	
	[1, 1, 2]	[0, 0, 0]	[7, 10, 16]	[1, 1, 2]	[0, 0, 4]	[0, 0, 0]	[0, 2, 3]	[11, 15, 27]	

- 472 **Table2.** ICU-, ventilation-, and ECMO-day for seven regions and Japan. The total days
- and 0.25, 0.5, and 0.75 quartile days in brackets were shown. ICU; intensive care unit,
- 474 ECMO; extracorporeal membrane oxygenation.

-	Hokkaido	Tohoku	Kanto-	Tokai-	Kansai	Chugoku-	Kyusyu-	Japan	
	поккашо		Koshinetsu	Hokuriku	Kansai	Shikoku	Okinawa		
Intensivist									
critical case	37.3	5.3	26.7	8.6	27.7	3.9	13	19.1	
ventilation	34.7	4.2	22	6.4	25.5	3.5	10	15.9	
ECMO	6.7	1.1	5.1	2.1	3	0.4	3.5	3.2	
Category II institution									
critical case	116.7	12.5	213.2	43.5	261.5	21.4	43.5	106.3	
Ventilation	108.3	10	175.8	32.6	241	19	33.3	88.9	
ECMO	20.8	2.5	40.7	10.9	28.2	2.4	11.6	17.7	
ECMO project									
ECMO	125	12.5	105.7	45.5	45.8	16.7	66.7	62	

**Table 3.** The percentage of the number of patients requiring critical care, mechanical ventilation, and ECMO to the number of board-certified intensivists, Category II institutions, and ECMO project hospitals for each region in Japan at the peak of the epidemic. ICU; intensive care unit, Category II; a designated medical institution for Category II infectious diseases, TB; tuberculosis, ECMO; extracorporeal membrane oxygenation.







